Pharmaceuticals Europe

Europe Cancer Vaccines Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

Europe Cancer Vaccines Market Industry Trends and Forecast to 2034: Segmented by (Type, Indication, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Europe · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $1.47 Bn Placeholder estimate
Estimate 2025 $1.62 Bn 18.8% of the global market
Projected 2034 $3.85 Bn 137.7% Adds $2.23 Bn over 9 forecast years
CAGR 2025–2034 10.1% Faster than 65% of 180 Pharmaceuticals markets here
Key players 5
  • Europe is 18.76% of the global market.
  • Among regions, the largest is North America at $4.06 Bn.
  • Fastest growing: APAC at 12.4% a year.
  • Europe ranks 3rd of 6 by size among regions.

Market size projection

Europe

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$2.23 Bn total, 2026–2034

Year-by-year market size, 2024–2034
Cancer Vaccines Market market size by year, Europe
YearMarket sizeChange that yearSince 2025
2024 (estimate) $1.47 Bn — —
2025 (base) $1.62 Bn +$148.5 Mn —
2026 (forecast) $1.78 Bn +$163.4 Mn +10.1%
2027 (forecast) $1.96 Bn +$180.0 Mn +21.2%
2028 (forecast) $2.16 Bn +$198.1 Mn +33.5%
2029 (forecast) $2.38 Bn +$218.1 Mn +46.9%
2030 (forecast) $2.62 Bn +$240.2 Mn +61.8%
2031 (forecast) $2.88 Bn +$264.4 Mn +78.1%
2032 (forecast) $3.17 Bn +$291.1 Mn +96.1%
2033 (forecast) $3.49 Bn +$320.5 Mn +115.9%
2034 (forecast) $3.85 Bn +$352.9 Mn +137.7%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Europe Cancer Vaccines Market Analysis at a glance
Market size, 2025$1.62 Bn placeholder estimate
Forecast, 2034$3.85 Bn placeholder estimate
Growth (CAGR), 2025–203410.1% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsType, indication and end user (see all)
Key playersModerna, Merck & Co., Inc., BioNTech, Dendreon Pharmaceuticals LLC, Gritstone bio (see all)
Regulator in EuropeEMASource: European Medicines Agency. Checked 14 Nov 2026.
Active clinical trials39 in EuropeSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Europe. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Europe Cancer Vaccines Market Analysis Executive Summary

Cancer vaccines train the immune system to recognise and attack cancer, including personalised mRNA vaccines and preventive vaccines.

Key segments of the cancer Vaccines market include type (Personalized Neoantigen Vaccines, Preventive Vaccines and Dendritic Cell Vaccines) and indication (Melanoma, Lung Cancer and Prostate Cancer).

Bar chart: Europe Cancer Vaccines market size, 2024–2034, placeholder estimates. $1.47 Bn in 2024, $1.62 Bn in 2025 and $3.85 Bn in 2034, 10.1% CAGR.
Europe Cancer Vaccines market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Europe Cancer Vaccines Market Dynamics

Market Growth Drivers

Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the cancer Vaccines market. Faster approvals and new combinations are improving survival.

Opportunity

Biomarker-led treatment, earlier lines of therapy and expansion into emerging markets offer strong growth for the cancer Vaccines market.

Market Restraints

High treatment costs, drug resistance, side effects and unequal access to cancer centres hold back the cancer Vaccines market, especially in low- and middle-income countries.

Competitive Landscape for Cancer Vaccines Market in Europe

The cancer Vaccines market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Cancer Vaccines Market in Europe

Cancer Vaccines in Europe: rules, payment and research

In the EU, many new medicines are authorised once for every member state by the European Commission, after review by the European Medicines Agency (EMA).⁠[1] In the countries we cover here, medicines are approved by ANSM (France)⁠[2], BfArM (Germany)⁠[3], AIFA (Italy)⁠[4], Ministry of Health (Russia)⁠[5], AEMPS (Spain)⁠[6] and MHRA (UK)⁠[7]. Each country runs its own health system and decides prices and reimbursement; since January 2025, EU countries also share joint clinical assessments of some new medicines.⁠[8] ClinicalTrials.gov lists 39 studies on Cancer Vaccines that are recruiting, active or about to start in Europe.⁠[9]

[1] European Medicines Agency. Checked 14 Nov 2026.

[2] ANSM, French medicines agency. Checked 14 Nov 2026.

[3] Federal Institute for Drugs and Medical Devices (BfArM). Checked 14 Nov 2026.

[4] Italian Medicines Agency (AIFA). Checked 14 Nov 2026.

[5] Ministry of Health of the Russian Federation. Checked 14 Nov 2026.

[6] Spanish Agency of Medicines and Medical Devices (AEMPS). Checked 14 Nov 2026.

[7] Medicines and Healthcare products Regulatory Agency. Checked 14 Nov 2026.

[8] European Commission, health technology assessment. Checked 14 Nov 2026.

[9] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Europe. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for cancer Vaccines. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Europe.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Cancer Vaccines right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Cancer Vaccines in context

Free data on this topic

Quick answers

Frequently asked questions

How big is the Cancer Vaccines market in Europe?
Placeholder estimate: about $1.62 Bn in 2025, rising to about $3.85 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Cancer Vaccines market in Europe growing?
Placeholder estimate: about 10.1% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Cancer Vaccines market report cover?
The report splits the market by type (Personalized Neoantigen Vaccines, Preventive Vaccines, Dendritic Cell Vaccines, Viral Vector Vaccines), indication (Melanoma, Lung Cancer, Prostate Cancer, Cervical Cancer) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Cancer Vaccines market?
Key players include Moderna, Merck & Co., Inc., BioNTech, Dendreon Pharmaceuticals LLC and Gritstone bio.
What is driving the Cancer Vaccines market?
Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the cancer Vaccines market. Faster approvals and new combinations are improving survival.
Who regulates Cancer Vaccines in Europe?
In the EU, many new medicines are authorised once for every member state by the European Commission, after review by the European Medicines Agency (EMA). Source: European Medicines Agency. Checked 14 Nov 2026.
How is healthcare paid for in Europe?
Each country runs its own health system and decides prices and reimbursement; since January 2025, EU countries also share joint clinical assessments of some new medicines. Source: European Commission, health technology assessment. Checked 14 Nov 2026.
How many clinical trials on Cancer Vaccines are running in Europe?
39 studies are recruiting, active or about to start in Europe, counted across the 6 countries we report on there, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Europe. Retrieved 12 Nov 2026.
How much research is published on Cancer Vaccines?
PubMed lists 2,635 papers on Cancer Vaccines added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in Europe

See all

Related on oncology and vaccines

See the topic